SCOPUS 정보 검색 플랫폼

Volumn 19, Issue 8, 2013, Pages 1003-1004

Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes

(2) Rudick, Richard A a Fisher, Elizabeth a

a LERNER RESEARCH INSTITUTE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; ANTIINFLAMMATORY AGENT; BETA INTERFERON; GADOLINIUM; MYELIN; NATALIZUMAB; PLACEBO;

ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CONTROLLED CLINICAL TRIAL (TOPIC); DEMYELINATION; DISEASE SEVERITY; DRUG EFFICACY; GRAY MATTER; HUMAN; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; TISSUE INJURY; WHITE MATTER;

EID: 84879774740 PISSN: 13524585 EISSN: 14770970 Source Type: Journal
DOI: 10.1177/1352458513482385 Document Type: Article

Times cited : (11)

References (10)

1
- 0032576752
- Axonal transection in the lesions of multiple sclerosis
- DOI 10.1056/NEJM199801293380502
- Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 ; 338: 278-285 (Pubitemid 28065253)
- (1998) New England Journal of Medicine , vol.338 , Issue.5 , pp. 278-285
- Trapp, B.D.¹ Peterson, J.² Ransohoff, R.M.³ Rudick, R.⁴ Mork, S.⁵ Bo, L.⁶

2
- 22544457629
- Brain atrophy and lesion load in a large population of patients with multiple sclerosis
- DOI 10.1212/01.wnl.0000168837.87351.1f
- Tedeschi G, Lavorgna L, Russo P, et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology. 2005 ; 65: 280-285 (Pubitemid 41022375)
- (2005) Neurology , vol.65 , Issue.2 , pp. 280-285
- Tedeschi, G.¹ Lavorgna, L.² Russo, P.³ Prinster, A.⁴ Dinacci, D.⁵ Savettieri, G.⁶ Quattrone, A.⁷ Livrea, P.⁸ Messina, C.⁹ Reggio, A.¹⁰ Bresciamorra, V.¹¹ Orefice, G.¹² Paciello, M.¹³ Brunetti, A.¹⁴ Coniglio, G.¹⁵ Bonavita, S.¹⁶ Di Costanzo, A.¹⁷ Bellacosa, A.¹⁸ Valentino, P.¹⁹ Quarantelli, M.²⁰ more..

3
- 34547886078
- Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis
- DOI 10.1001/archneur.64.8.1157
- Amato MP, Portaccio E, Goretti B, et al. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol. 2007 ; 64: 1157-1161 (Pubitemid 47258075)
- (2007) Archives of Neurology , vol.64 , Issue.8 , pp. 1157-1161
- Amato, M.P.¹ Portaccio, E.² Goretti, B.³ Zipoli, V.⁴ Battaglini, M.⁵ Bartolozzi, M.L.⁶ Stromillo, M.L.⁷ Guidi, L.⁸ Siracusa, G.⁹ Sorbi, S.¹⁰ Federico, A.¹¹ De Stefano, N.¹²

4
- 54949093619
- Brain atrophy assessment in multiple sclerosis: Importance and limitations
- Giorgio A, Battaglini M, Smith SM, et al. Brain atrophy assessment in multiple sclerosis: Importance and limitations. Neuroimaging Clin N Am. 2008 ; 18: 675-686
- (2008) Neuroimaging Clin N Am , vol.18 , pp. 675-686
- Giorgio, A.¹ Battaglini, M.² Smith, S.M.³

5
- 84879775042
- 4th ed.Cambridge: Cambridge University Press, 2011. pp.128-149. Cohen JA Rudick RA, ed. Cambridge: Cambridge University Press;
- Fisher E Multiple Sclerosis Therapeutics. 4 th ed.Cambridge: Cambridge University Press, 2011. pp.128-149. Cohen JA Rudick RA, ed. Cambridge: Cambridge University Press ; 2011: 128-149.
- (2011) Multiple Sclerosis Therapeutics , pp. 128-149
- Fisher, E.¹

6
- 0037069230
- Eight-year follow-up study of brain atrophy in patients with MS
- Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002 ; 59: 1412-1420 (Pubitemid 35285996)
- (2002) Neurology , vol.59 , Issue.9 , pp. 1412-1420
- Fisher, E.¹ Rudick, R.A.² Simon, J.H.³ Cutter, G.⁴ Baier, M.⁵ Lee, J.-C.⁶ Miller, D.⁷ Weinstock-Guttman, B.⁸ Mass, M.K.⁹ Dougherty, D.S.¹⁰ Simonian, N.A.¹¹

7
- 0033544320
- Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
- Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology. 1999 ; 53: 1698-1704 (Pubitemid 29530342)
- (1999) Neurology , vol.53 , Issue.8 , pp. 1698-1704
- Rudick, R.A.¹ Fisher, E.² Lee, J.-C.³ Simon, J.⁴ Jacobs, L.⁵

8
- 34247513840
- MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
- DOI 10.1212/01.wnl.0000260064.77700.fd, PII 0000611420070424000012
- Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007 ; 68: 1390-1401 (Pubitemid 46659091)
- (2007) Neurology , vol.68 , Issue.17 , pp. 1390-1401
- Miller, D.H.¹ Soon, D.² Fernando, K.T.³ MacManus, D.G.⁴ Barker, G.J.⁵ Yousry, T.A.⁶ Fisher, E.⁷ O'Connor, P.W.⁸ Phillips, J.T.⁹ Polman, C.H.¹⁰ Kappos, L.¹¹ Hutchinson, M.¹² Havrdova, E.¹³ Lublin, F.D.¹⁴ Giovannoni, G.¹⁵ Wajgt, A.¹⁶ Rudick, R.¹⁷ Lynn, F.¹⁸ Panzara, M.A.¹⁹ Sandrock, A.W.²⁰ more..

9
- 47549113346
- Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
- Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008 ; 71: 136-144
- (2008) Neurology , vol.71 , pp. 136-144
- Zivadinov, R.¹ Reder, A.T.² Filippi, M.³

10
- 77953476309
- Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebo-controlled, parallel-group trial
- Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010 ; 9: 681-688
- (2010) Lancet Neurol , vol.9 , pp. 681-688
- Kapoor, R.¹ Furby, J.² Hayton, T.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.